Progressive Supranuclear Palsy (PSP) Therapies market Size, Share and Industry Trends by 2030
In 2019, owing to the failure to meet the desired endpoints, two big pharma players, Abbvie and Biogen announced their decision to terminate the development of their pipeline anti-tau antibodies for PSP, namely ABBV-8E12 and gosuranemab, respectively.
Get Detailed Report: https://www.rootsanalysis.com/....reports/progressive-